EpiGenic Therapeutics Secures $32 Million Series A Financing to Advance Breakthrough Epigenetic Therapies

ShanghaiAugust 30, 2023/PR Newswire/ --EpigenicEpigenic Therapeutics, Inc. (hereinafter referred to as "Epigenic")) PromulgationEpigenic Completes $32 Million Series A Financing. This round of financing was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Ventures. The funds will be used for preclinical development and early clinical validation of two leading projects. The company will continue to invest in the research and development of its future pipeline, expand the leadership team, and maintain ongoing investment in its established core technology platforms.

Epigenic Therapeutics, Inc. is a leading biotechnology company dedicated to developing next-generation epigenetic regulation technologies for the treatment of chronic diseases.Compared with the DNA cleavage approach of traditional gene-editing tools, Epigenic's proprietary EPIREG™ technology offers a completely different solution. Through precise DNA methylation and histone modification, EPIREG™ can silence target genes efficiently and durably, providing revolutionary and innovative treatment options for patients with chronic diseases. Notably, this solution effectively addresses safety concerns associated with traditional gene editing.

Dr. Bao Hong Zhang, co-founder and CEO of Epigenic, stated: "We are greatly honored to receive support from top global investors. In the second year since our company's establishment, we have achieved breakthrough progress in transforming cutting-edge science into life-saving epigenetic drugs. Epigenic has developed targeted therapeutic strategies and will continue to fulfill its mission by pioneering innovations in the field of epigenetic gene drug development, striving to benefit patients as soon as possible."

Dr. Chen Kan, Partner at Qiming Venture Partners, stated: "Gene therapy is one of the most exciting biotechnology fields in recent years. Qiming Venture Partners has been closely monitoring the latest technological advancements and breakthrough treatments, as well as how to apply these technologies to meet unmet medical needs. Epigenic Therapeutics utilizes its globally leading epigenetic regulation technology to develop innovative therapies for various chronic diseases. It has a passionate and experienced team, establishing a unique technology platform and product pipeline. The company has been steadily and efficiently advancing its development, and we look forward to the company bringing new hope to patients as soon as possible."

OrbiMed Asia Partner Da Song Wang stated: "Compared with other genetic tools, epigenetic regulation technology has demonstrated superior efficiency, durability, and safety. Epigenic Therapeutics is a leader in this field, leveraging the unique advantages of its platform to develop potentially best-in-class therapeutic drugs. We are highly impressed by Epigenic’s preclinical data and the execution capability of its leadership team, and we look forward to supporting Epigenic in advancing its two drug candidates into clinical trials."